176 related articles for article (PubMed ID: 12698500)
1. Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications.
Armijo JA; Sánchez BM; Peralta FG; González-Ruiz M; Cuadrado A; Verdejo A; Cos MA; Arjona R
Biopharm Drug Dispos; 2003 May; 24(4):165-71. PubMed ID: 12698500
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
[TBL] [Abstract][Full Text] [Related]
3. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
Cova D; Cuglituri G; Rossini L; Bonfardeci G
Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):273-5. PubMed ID: 2737795
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen.
Wang P; Qi M; Zhong D; Fang L
Biomed Chromatogr; 2003 Jan; 17(1):58-61. PubMed ID: 12583008
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage].
Fuchs WS; von Nieciecki A; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
Arzneimittelforschung; 1998 May; 48(5A):589-92. PubMed ID: 9676350
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics and pharmacodynamics of sustained-release theophylline formulation, Slo-bid, in both single and multiple dosing studies of asthmatic children].
Iwasaki E; Baba M
Arerugi; 1989 Mar; 38(3):263-71. PubMed ID: 2751433
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily.
Götz J; Sauter R; Steinijans VW; Jonkman JH
Int J Clin Pharmacol Ther; 1994 Apr; 32(4):168-73. PubMed ID: 8032575
[TBL] [Abstract][Full Text] [Related]
8. Theophylline therapeutic drug monitoring in the case of a new sustained-release pellet formulation for once-daily evening administration.
Steinijans VW; Trautmann H; Sauter R; Staudinger H
Arzneimittelforschung; 1988 Aug; 38(8A):1251-3. PubMed ID: 3190814
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the theophylline pharmacokinetics of sustained-release theophylline (Theodur) dry syrup in children].
Okuma M; Iikura Y
Arerugi; 1999 Jun; 48(6):589-96. PubMed ID: 10423899
[TBL] [Abstract][Full Text] [Related]
10. The effects of cefonicid on the pharmacokinetics of a once-a-day theophylline formulation.
Cazzola M; Lobefalo G; Lupis F; Vanacore L; Martucci P; D'Amato G
Int J Clin Pharmacol Res; 1989; 9(3):169-73. PubMed ID: 2663736
[TBL] [Abstract][Full Text] [Related]
11. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
Fontana G; Cresci F; Lo Sapio P; Panuccio P
Int J Clin Pharmacol Res; 1987; 7(5):351-6. PubMed ID: 3667008
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of a new fluid theophylline sustained-release drug form. Microcapsules in a sachet].
Fuchs WS; Weiss G; von Nieciecki A; Laicher A; Gay S; Pabst G; Müller M
Arzneimittelforschung; 1998 May; 48(5A):612-7. PubMed ID: 9676354
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: microcaps as sachet.
Fuchs WS; Weiss G; Von Nieciecki A; Laicher A; Gay S; Pabst G; Müller M
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):558-63. PubMed ID: 8996853
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of the single point method for theophylline maintenance dose prediction.
Abad J; Pastor A; Prieto L; Palop J; Jiménez Torres V; Castro J
Allergol Immunopathol (Madr); 1987; 15(6):355-9. PubMed ID: 3445876
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson DJ; Vearer D
Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.
Bachmann K; Jauregui L; Sides G; Sullivan TJ
J Clin Pharmacol; 1993 Sep; 33(9):861-5. PubMed ID: 8227485
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of theophylline in sustained-release formulation in young asthmatics].
Witschital K; Fuchs WS; Heese U; von Nieciecki A; Laicher A
Arzneimittelforschung; 1998 May; 48(5A):593-6. PubMed ID: 9676351
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of chronic obstructive respiratory disease with a new purified theophylline preparation in delayed-action form].
Kaik G
Wien Med Wochenschr; 1984 Apr; 134(7):163-9. PubMed ID: 6741156
[TBL] [Abstract][Full Text] [Related]
19. Non-interference of xibornol on the theophylline blood levels.
Fraschini F; Scaglione F; Maierna G; Savio G; Gattei G; Falchi M
Int J Clin Pharmacol Res; 1988; 8(1):43-6. PubMed ID: 3366502
[TBL] [Abstract][Full Text] [Related]
20. [Comparative study of plasma levels of 2 delayed-action theophyllines: Theostat 200 and Theodur 200, after a single evening dose].
Philip-Joet F; Bruguerolle B; Lagier F; Arnaud A
Rev Pneumol Clin; 1986; 42(6):279-83. PubMed ID: 3563255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
